Tscan Therapeutics, Inc.
Clinical trials sponsored by Tscan Therapeutics, Inc., explained in plain language.
-
Supercharged donor cells aim to keep blood cancer away after transplant
Disease control Recruiting nowThis early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely prevent blood cancers like AML, MDS, or ALL from coming back after a stem cell transplant. About 75 adults will receive either the engineered cells or standard care. The m…
Phase: PHASE1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:08 UTC
-
15-Year watch begins for pioneering cancer cell therapy recipients
Knowledge-focused Recruiting nowThis long-term follow-up study tracks about 1,000 people who previously received an experimental T-cell therapy (TSC-100 or TSC-101) for blood cancers like AML, ALL, or MDS. Researchers will monitor participants for 15 years to check for any late side effects and to see how long …
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 16, 2026 22:35 UTC
-
Scientists hunt for immune system targets in autoimmune patients
Knowledge-focused Recruiting nowThis study collects tissue and blood samples from 300 people with autoimmune diseases like Crohn's, multiple sclerosis, and celiac disease. Researchers will look for immune cells (T cells) that are active in inflamed tissues to find what they are attacking. The goal is to discove…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:54 UTC